# Choriogonadotropin Alfa

## Ovidrel inj 250mcg

| 藥物代碼 | IOVI |
| :--- | :--- |
| 適應症 | Women undergoing superovulation prior to assisted reproductive techniques such as in-vitro fertilisation \(IVF\) ,Anovulatory or oligo-ovulatory women |
| 副作用 | Local inj site reactions, headache, fatigue, GI disturbances, mild or moderate ovarian hyperstimulation syndrome. Ectopic pregnancy, ovarian torsion & other complications in some patients after hCG administration. Uncommonly, depression, irritability, restlessness, diarrhoea, severe ovarian hyperstimulation syndrome, breast pain. Rarely, thromboembolism. |
| 禁忌 | Hypothalamic & pituitary tumours; ovarian enlargement or cyst due to reasons other than polycystic ovarian disease; gynaecological haemorrhage of unknown aetiology; ovarian, uterine or mammary carcinoma; extrauterine pregnancy in the previous 3 months; active thromboembolic disorders; primary ovarian failure, sexual organ malformations incompatible with pregnancy; fibroid uterine tumours incompatible with pregnancy; postmenopausal women. Pregnancy & lactation. |
| 藥物保存方式 | N/A |
| 用法用量 | Women undergoing superovulation prior to assisted reproductive techniques such as in-vitro fertilisation \(IVF\) 250 mcg SC 24-48 hr after the last administration of an FSH or hMG prep, when optimal stimulation of follicular growth is achieved Anovulatory or oligo-ovulatory women 250 mcg SC 24-48 hr after optimal stimulation of follicular growth is achieved. The patient is recommended to have coitus on the day of, & the day after inj. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | SC |
| 乾粉稀釋液 | 使用廠商所附稀釋溶液溶解 |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

